Comparison of cinoxacin and co-trimoxazole in the treatment of urinary tract infections.

Abstract

A randomised single-blind clinical trial compared cinoxacin (500 mg every 12 hours) to co-trimoxazole (160 mg trimethoprim, 800 mg sulphamethoxazole every 12 hours) in the treatment of 63 patients with urinary tract infections. The symptomatic response was 73% for both drugs. Bacterial eradication was achieved in 81% and 100% of patients receiving cinoxacin and co-trimoxazole respectively. Three patients receiving co-trimoxazole stopped treatment because of adverse reactions. We conclude that cinoxacin is an effective and safe antibacterial agent in the treatment of urinary tract infections.

• Authors: P de Jersey, H O Wooller
• Journal: The Medical journal of Australia (Med J Aust) Vol. 1 Issue 6 Pg. 267-8 (Mar 20 1982) ISSN: 0025-729X [Print] Australia
• PMID: 7045606 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Infective Agents, Urinary
• Drug Combinations
• Pyridazines
• Trimethoprim, Sulfamethoxazole Drug Combination
• Trimethoprim
• Sulfamethoxazole
• Cinoxacin

Topics

• Adolescent
• Adult
• Aged
• Anti-Infective Agents, Urinary (adverse effects, therapeutic use)
• Bacteriuria (drug therapy)
• Cinoxacin (therapeutic use)
• Clinical Trials as Topic
• Cystitis (drug therapy)
• Drug Combinations (adverse effects, therapeutic use)
• Drug Hypersensitivity (etiology)
• Escherichia coli Infections (drug therapy)
• Female
• Humans
• Male
• Middle Aged
• Nausea (chemically induced)
• Pyelonephritis (drug therapy)
• Pyridazines (therapeutic use)
• Random Allocation
• Sulfamethoxazole (adverse effects, therapeutic use)
• Trimethoprim (adverse effects, therapeutic use)
• Trimethoprim, Sulfamethoxazole Drug Combination
• Urinary Tract Infections (drug therapy)